Broadfin Capital, LLC - Q4 2019 holdings

$747 Million is the total value of Broadfin Capital, LLC's 40 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 63.6% .

 Value Shares↓ Weighting
SPY  SPDR S&P 500 ETF TRput$141,618,000
+8.5%
440,0000.0%18.96%
-21.4%
IWM NewISHARES TRput$132,536,000800,000
+100.0%
17.75%
XBI SellSPDR SERIES TRUSTput$33,289,000
-37.6%
350,000
-50.0%
4.46%
-54.8%
BHVN BuyBIOHAVEN PHARMACTL HLDG CO Lcall$32,664,000
+56.6%
600,000
+20.0%
4.37%
+13.4%
BDSI  BIODELIVERY SCIENCES INTL IN$27,176,000
+50.1%
4,300,0660.0%3.64%
+8.7%
VRAY BuyVIEWRAY INC$23,524,000
+170.3%
5,574,366
+85.7%
3.15%
+95.8%
AMRN SellAMARIN CORP PLCspons adr new$22,496,000
-5.4%
1,049,244
-33.1%
3.01%
-31.5%
BHVN SellBIOHAVEN PHARMACTL HLDG CO L$22,284,000
+0.3%
409,338
-23.1%
2.98%
-27.4%
ALKS BuyALKERMES PLC$21,083,000
+334.0%
1,033,500
+315.1%
2.82%
+214.4%
QTNT BuyQUOTIENT LTD$18,965,000
+297.9%
1,994,183
+225.1%
2.54%
+188.2%
EIGR SellEIGER BIOPHARMACEUTICALS INC$18,422,000
+31.4%
1,236,368
-9.6%
2.47%
-4.8%
STAA NewSTAAR SURGICAL CO$16,253,000462,118
+100.0%
2.18%
XENT SellINTERSECT ENT INC$15,712,000
+18.6%
631,023
-19.0%
2.10%
-14.1%
PGNX BuyPROGENICS PHARMACEUTICALS IN$15,580,000
+94.6%
3,060,923
+93.2%
2.09%
+40.9%
NSTG BuyNANOSTRING TECHNOLOGIES INC$15,457,000
+546.2%
555,600
+401.4%
2.07%
+368.3%
IOVA SellIOVANCE BIOTHERAPEUTICS INC$14,762,000
-28.3%
533,301
-52.9%
1.98%
-48.1%
DERM BuyDERMIRA INC$13,588,000
+266.8%
896,334
+54.6%
1.82%
+165.5%
REPH SellRECRO PHARMA INC$13,217,000
+20.8%
721,073
-27.0%
1.77%
-12.5%
LNTH NewLANTHEUS HLDGS INC$12,674,000617,953
+100.0%
1.70%
VAPO NewVAPOTHERM INC$12,198,0001,003,099
+100.0%
1.63%
SIEN SellSIENTRA INC$11,506,000
-11.3%
1,286,987
-35.7%
1.54%
-35.7%
VCEL BuyVERICEL CORP$10,791,000
+200.7%
620,199
+161.6%
1.44%
+117.6%
LJPC BuyLA JOLLA PHARMACEUTICAL CO$10,564,000
+560.2%
2,688,068
+1378.2%
1.42%
+378.0%
ALXN NewALEXION PHARMACEUTICALS INC$8,987,00083,100
+100.0%
1.20%
SLGL SellSOL GEL TECHNOLOGIES$8,949,000
+76.7%
521,819
-7.4%
1.20%
+28.0%
RLMD NewRELMADA THERAPEUTICS INC$8,608,000220,724
+100.0%
1.15%
AUPH NewAURINIA PHARMACEUTICALS INC$8,104,000400,000
+100.0%
1.08%
AVDL SellAVADEL PHARMACEUTICALS PLCsponsored adr$7,769,000
-39.8%
1,029,012
-66.8%
1.04%
-56.4%
XCUR BuyEXICURE INC$7,744,000
+32.4%
2,707,851
+17.1%
1.04%
-4.1%
ZGNX SellZOGENIX INC$7,034,000
+27.3%
134,937
-2.2%
0.94%
-7.8%
ICUI  ICU MED INC$5,614,000
+17.3%
30,0000.0%0.75%
-15.0%
LMNX NewLUMINEX CORP DEL$4,807,000207,553
+100.0%
0.64%
ALKS NewALKERMES PLCcall$4,080,000200,000
+100.0%
0.55%
SSKN SellSTRATA SKIN SCIENCES INC$3,826,000
-39.0%
1,839,372
-36.9%
0.51%
-55.8%
ANAB NewANAPTYSBIO INC$3,601,000221,600
+100.0%
0.48%
ACRS BuyACLARIS THERAPEUTICS INC$3,568,000
+103.9%
1,888,039
+16.5%
0.48%
+47.5%
MYL NewMYLAN N V$3,015,000150,000
+100.0%
0.40%
HRTX SellHERON THERAPEUTICS INC$2,109,000
+16.1%
89,730
-8.7%
0.28%
-16.1%
SCYX NewSCYNEXIS INC$1,820,0002,000,000
+100.0%
0.24%
PTN  PALATIN TECHNOLOGIES INC$819,000
-14.0%
1,047,3100.0%0.11%
-37.5%
AMAG ExitAMAG PHARMACEUTICALS INC$0-100,000
-100.0%
-0.21%
HRTX ExitHERON THERAPEUTICS INCcall$0-100,000
-100.0%
-0.34%
ADMA ExitADMA BIOLOGICS INC$0-505,900
-100.0%
-0.42%
GWPH ExitGW PHARMACEUTICALS PLCads$0-30,000
-100.0%
-0.64%
SIBN ExitSI BONE INC$0-223,291
-100.0%
-0.73%
ATRS ExitANTARES PHARMA INC$0-1,336,700
-100.0%
-0.83%
CPRX ExitCATALYST PHARMACEUTICALS INC$0-880,303
-100.0%
-0.86%
XGN ExitEXAGEN INC$0-311,284
-100.0%
-0.89%
SBBP ExitSTRONGBRIDGE BIOPHARMA PLC$0-2,578,003
-100.0%
-1.14%
RTRX ExitRETROPHIN INC$0-610,414
-100.0%
-1.31%
GBT ExitGLOBAL BLOOD THERAPEUTICS IN$0-177,016
-100.0%
-1.59%
ABBV ExitABBVIE INC$0-154,500
-100.0%
-2.16%
WMGI ExitWRIGHT MED GROUP N V$0-618,500
-100.0%
-2.36%
NVRO ExitNEVRO CORP$0-150,510
-100.0%
-2.39%
MRTX ExitMIRATI THERAPEUTICS INCcall$0-200,000
-100.0%
-2.88%
AGN ExitALLERGAN PLC$0-96,504
-100.0%
-3.00%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

  • Broadfin Healthcare Master Fund Ltd #1
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2020-02-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
BIODELIVERY SCIENCES INTL IN27Q4 20194.8%
HERON THERAPEUTICS INC24Q4 20199.0%
LA JOLLA PHARMACEUTICAL CO24Q4 20197.7%
RECRO PHARMA INC24Q4 20194.1%
ANTARES PHARMA INC24Q3 20193.4%
RETROPHIN INC23Q3 20197.0%
ARATANA THERAPEUTICS INC22Q2 20198.1%
MIRATI THERAPEUTICS INC22Q1 20197.9%
CATALYST PHARM PARTNERS INC22Q3 20196.2%
ANGIODYNAMICS INC21Q3 20186.6%

View Broadfin Capital, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Broadfin Capital, LLC Q4 2019 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Eiger BioPharmaceuticals, Inc.Sold outJanuary 04, 202100.0%
LA JOLLA PHARMACEUTICAL COSold outJanuary 04, 202100.0%
STRATA Skin Sciences, Inc.June 23, 20201,529,3924.5%
Teligent, Inc.Sold outFebruary 25, 202000.0%
Neos Therapeutics, Inc.Sold outFebruary 14, 202000.0%
Aclaris Therapeutics, Inc.February 13, 20201,888,0394.6%
Adamas Pharmaceuticals IncSold outFebruary 13, 202000.0%
ADMA BIOLOGICS, INC.Sold outFebruary 13, 202000.0%
AVADEL PHARMACEUTICALS PLCFebruary 13, 20201,029,0122.8%
CATALYST PHARMACEUTICALS, INC.Sold outFebruary 13, 202000.0%

View Broadfin Capital, LLC's complete significant-ownership history.

Latest filings
TypeFiled
42022-03-22
42022-02-15
42022-01-31
42021-11-22
42021-11-15
42021-11-09
42021-08-10
42021-05-13
SC 13G/A2021-01-04
SC 13G/A2021-01-04

View Broadfin Capital, LLC's complete filings history.

Compare quarters

Export Broadfin Capital, LLC's holdings